Biologic Agent

PreclinicalSmall molecule

QQianfoshan Hospital

Biologic Agent is one of 26 small molecule programs targeting Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Aclidinium Bromide

Atrovent

2 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Efficacy and Safety

NCT07362693

Q4 2032

Recruiting

Inflammation

NCT07132333

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

Not yet recruiting·QQianfoshan Hospital··NCT07362693·50 enrolled

Treatment1 trial

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Completed·PPsoriasis Treatment Center of Central New Jersey··NCT03964168·3 enrolled

Asthma1 trial

This is a 6-month Observational Study. Patients Included Will be Those Referred With a Possible Diagnosis or an Established Diagnosis of Asthma. It Will Look at the Association of the Asthma Microbiome and Disease Characteristics, Severity and Treatment Response.

Unknown status·RRoyal College of Surgeons, Ireland··NCT06028204·60 enrolled

Inflammation1 trial

Molecular Inflammation Board at the Center for Personalized Medicine

Recruiting·UUniversity Hospital Tuebingen··NCT07132333·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Biologic Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biologic Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biologic Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qianfoshan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: QQianfoshan Hospital

Biologic Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2032

Trials by Indication[1]

Efficacy and Safety1 trial

Treatment1 trial

Asthma1 trial

Inflammation1 trial

References

Drug Info

Quick Facts

Related News